MTOR and hepatocellular carcinoma: Our study results displayed that since LAGE3 might promote tumor development in HCC via PI3K/AKT/mTOR and Ras/RAF/MAPK pathways, the development of LAGE3 target drugs may be a new treatment strategy for HCC patients.